If your child or loved one has been
diagnosed with MCT8 deficiency,
participating in clinical research
may be right for your family.
Currently enrolling in sites throughout the United States, the ReTRIACt study is evaluating the safety and efficacy of an investigational drug in males with MCT8 deficiency, aged 4 years or older, that targets the underlying pathology of MCT8 deficiency.
Why participate?
- Clinical research studies are necessary to advance new and potentially improved future treatments for MCT8 deficiency.
- Study participants receive study-related medical exams and study drug at no cost.
- Travel accommodations will be provided and financial assistance for travel is available.
- Following completion of the study, all eligible patients will be able to continue receiving investigational drug via a compassionate-use program.
Who can participate?
- Males at least 4 years of age with a diagnosed pathogenic mutation in the MCT8 gene.
- Able to visit your closest research site approximately 3 times, with at-home nurse and virtual visits, over a period of up to 6 months.
- Must reside in the United States.
- Other criteria for eligibility apply.
Your participation matters. Want to learn more?
Click on the buttons below to confirm your consent.
This will allow us to contact you via email or phone with this information:
Trial Information
https://clinicaltrials.gov under identifier NCT05579327
ReTRIACt study is sponsored by Rare Thyroid Therapeutics AB, a fully owned subsidiary of Egetis Therapeutics AB (publ).